In the past week, HOTH stock has gone down by -1.93%, with a monthly gain of 92.34% and a quarterly surge of 68.27%. The volatility ratio for the week is 11.94%, and the volatility levels for the last 30 days are 25.66% for Hoth Therapeutics Inc The simple moving average for the last 20 days is 16.68% for HOTH stock, with a simple moving average of 52.93% for the last 200 days.
Is It Worth Investing in Hoth Therapeutics Inc (NASDAQ: HOTH) Right Now?
Moreover, the 36-month beta value for HOTH is 0.86. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HOTH is 6.84M and currently, short sellers hold a 9.26% of that float. On January 23, 2025, HOTH’s average trading volume was 9.17M shares.
HOTH) stock’s latest price update
Hoth Therapeutics Inc (NASDAQ: HOTH) has seen a rise in its stock price by 8.88 in relation to its previous close of 1.36. However, the company has experienced a -1.93% decline in its stock price over the last five trading sessions. prnewswire.com reported 2025-01-21 that IP will be used to pursue further indications for HT-001 Cancer Therapeutic NEW YORK, Jan. 21, 2025 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio through the acquisition and expansion of patent applications to its innovative therapeutic pipeline. These newly secured patents reflect Hoth’s commitment to pioneering cutting-edge treatments that address unmet medical needs, with a focus on enhancing therapeutic efficacy and broadening applications across various disease areas.
Analysts’ Opinion of HOTH
Many brokerage firms have already submitted their reports for HOTH stocks, with The Benchmark Company repeating the rating for HOTH by listing it as a “Speculative Buy.” The predicted price for HOTH in the upcoming period, according to The Benchmark Company is $10 based on the research report published on October 15, 2019 of the previous year 2019.
HOTH Trading at 46.77% from the 50-Day Moving Average
After a stumble in the market that brought HOTH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.03% of loss for the given period.
Volatility was left at 25.66%, however, over the last 30 days, the volatility rate increased by 11.94%, as shares surge +84.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +66.16% upper at present.
During the last 5 trading sessions, HOTH fell by -1.29%, which changed the moving average for the period of 200-days by +6.46% in comparison to the 20-day moving average, which settled at $1.2696. In addition, Hoth Therapeutics Inc saw 97.94% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HOTH starting from Knie Robb, who purchase 25,000 shares at the price of $0.67 back on Aug 16 ’24. After this action, Knie Robb now owns 58,131 shares of Hoth Therapeutics Inc, valued at $16,750 using the latest closing price.
Stock Fundamentals for HOTH
Current profitability levels for the company are sitting at:
- -126.48 for the present operating margin
- 0.5 for the gross margin
The net margin for Hoth Therapeutics Inc stands at -126.1. The total capital return value is set at -1.0. Equity return is now at value -83.41, with -73.63 for asset returns.
Based on Hoth Therapeutics Inc (HOTH), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -237.28. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -808.82.
Currently, EBITDA for the company is -0.15 million with net debt to EBITDA at 1.46. When we switch over and look at the enterprise to sales, we see a ratio of 38.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.16.
Conclusion
To wrap up, the performance of Hoth Therapeutics Inc (HOTH) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
